Dermatologicals
Refine search
Pharmaceutical
Anglo-American pharma company KalVista Pharmaceuticals has won approval from both the European Commission (EC) and Swiss Agency for Therapeutic Products, Swissmedic, for Ekterly (sebetralstat), a novel, oral plasma kallikrein inhibitor, for the symptomatic treatment of acute attacks of hereditary angioedema (HAE) in patients aged 12 years and older. 22 September 2025
Pharmaceutical
Important research news last week included US biotech aTyr Pharma posting disappointing Phase III results for its efzofitimod in pulmonary sarcoidosis, while Switzerland-based Roivant announced positive Phase III data on its dermatomyositis candidate brepocitinib. On the M&A front, Swiss pharma giant Roche announced plans to acquire US biotech 89bio and its liver disease candidate pegozafermin. Also of note, the US government’s vaccines advisory committee – ACIP -meeting last week adds to uncertainty over immunization policy. 21 September 2025
Biosimilars
South Korean firm Celltrion today showcased its longstanding commitment to expanding its biosimilar portfolio in the field of immuno-dermatology by attending the 2025 European Academy of Dermatology and Venereology (EADV) Congress. 19 September 2025
Biotechnology
Spanish drugmaker Almirall has announced new long-term results from the POSITIVE study, presented as a late-breaker at the 34th Congress of the European Academy of Dermatology and Venereology 2025 (EADV) in Paris, France. 19 September 2025
Pharmaceutical
Japanese pharma major Shionogi announced that its subsidiary Torii Pharmaceutical has received manufacturing and marketing approval of Ycanth (cantharidin) topical solution 0.71% for the treatment of molluscum contagiosum, a dermatological disease, in Japan. 19 September 2025
Biotechnology
US drug developer Nektar Therapeutics saw its shares rise 9% to $55.66 following release of new data from the ongoing REZOLVE-AD Phase IIb study of rezpegaldesleukin, an interleukin (IL)-2 pathway agonist and regulatory T-cell (Treg) proliferator. 18 September 2025
Biotechnology
Belgian biopharma UCB has announced three-year data from the BE HEARD trials for Bimzelx (bimekizumab) in moderate to severe hidradenitis suppurativa (HS). 17 September 2025
Biotechnology
US drug developer Oruka Therapeutics’ shares leapt as much as 20% in early trading, after it announced positive data from its Phase I trial of ORKA-001, its long-acting interleukin (IL)-23p19 antibody. 17 September 2025
Pharmaceutical
Switzerland-based Roivant and Priovant Therapeutics today announced positive results from the Phase III VALOR study evaluating brepocitinib in dermatomyositis (DM), with the news sending Roivant’s shares up12.8% to $16.02. 17 September 2025
Pharmaceutical
New data from the HS-OBTAIN Phase IIa study (clinical study identifier: show that treatment with brivekimig led to clinically-meaningful improvements in the primary endpoint of hidradenitis suppurativa (HS) clinical response (HiSCR50) in patients naïve to biologics with moderate-to-severe hidradenitis suppurativa (HS). 17 September 2025
Biotechnology
Positive high-level results from a pre-specified interim analysis of the Phase III TULIP-SC trial in patients with systemic lupus erythematosus (SLE) showed that the subcutaneous (SC) administration of AstraZeneca’s Saphnelo (anifrolumab) demonstrated a statistically-significant and clinically-meaningful reduction in disease activity compared to placebo. 17 September 2025
Biotechnology
China’s Junshi Biosciences announced that its recombinant humanized anti-interleukin (IL)-17A monoclonal antibody (code: JS005) has achieved positive results in a multicenter, randomized, double-blind, parallel, placebo-controlled pivotal registrational Phase III clinical study for the treatment of moderate to severe plaque psoriasis. 8 September 2025
Biotechnology
Significant research news last week included US drug developer Ionis Pharmaceuticals released impressive Phase III results for its olezarsen for the treatment of severe hypertriglyceridemia. On the deal-making front, Arrowhead Pharmaceuticals entered into an out-licensing deal for its ARO-SNCA pre-clinical siRNA therapy to Swiss pharma giant Novartis in a deal worth over $2 billion. Also, France’s Servier licensed ex-US rights for darovasertib for eye cancer from IDEAYA Biosciences in a deal worth up to $530 million. French pharma major Sanofi released what is called ’positive’ Phase III results for its atopic dermatitis candidate amlitelimab, but analysts were disappointed. 7 September 2025
Biotechnology
Colorado, USA-based biotech Enveda announced three major milestones in one on Thursday. 5 September 2025
Biotechnology
French pharma major Sanofi saw its shares fall more than 10% this morning following the publication of Phase III COAST 1 trial results for amlitelimab in adults and adolescents with atopic dermatitis, with analysts saying these were weaker-than-expected efficacy outcomes. 4 September 2025
Pharmaceutical
Italian pharma Fidia Farmaceutici today announces the acquisition of 100% of the share capital of Altacor, a UK-based specialist ophthalmology company with a growing portfolio of products including Clinitas, a dedicated line for dry eye treatment. 3 September 2025
Biosimilars
The European Commission (EC) has approved Chinese biopharma Bio-Thera Solutions BAT2206 (ustekinumab), a biosimilar referencing Stelara following a positive opinion from the European Medicines Agency's CHMP on June 19, 2025. 27 August 2025
Pharmaceutical
US pharma major AbbVie reported positive top-line results from the second of two pivotal studies of the Phase III UP-AA clinical program evaluating the safety and efficacy of upadacitinib (trade name Rinvoq) 15mg and 30mg, once daily in adult and adolescent patients with severe alopecia areata (AA) with a mean baseline SALT score of 84.0 (approximately 16% scalp hair coverage). 22 August 2025
Biotechnology
Celldex Therapeutics shares fell as much as 13% on Wednesday, after it posted mixed top-line results from its ongoing Phase II study of barzolvolimab in eosinophilic esophagitis (EoE), a chronic inflammatory disease of the esophagus. 21 August 2025
Pharmaceutical
Privately-held dermatology specialist LEO Pharma today revealed robust growth and significantly improved profitability, enabling an increase to the financial outlook for sales growth and adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) margin in first-half 2025 towards the upper-end of previously communicated expectations. 18 August 2025
Biotechnology
USA-based clinical-stage dermatology start-up Veradermics has announced the pricing of its upsized initial public offering of 15,077,647 shares of its common stock at an initial public offering price of $17.00 per share. All of the shares are being offered by Veradermics. 5 February 2026
Biosimilars
Russian drugmaker Binnopharm Group together with China’s Mabwell announced plans to localize the production of a monoclonal antibody (MAb)-based drug for the treatment of asthma and atopic dermatitis in Russia. 4 February 2026
Biotechnology
Belgium’s largest drugmaker UCB today announced three-year data from the BE HEARD trials^ for Bimzelx (bimekizumab) in moderate to severe HS. 4 February 2026
Biotechnology
US clinical-stage biotech Sagimet Biosciences’ shares rose 10% to $6.23 after it announced that China-based partner Ascletis Pharma reported positive top-line results in the open-label Phase III trial evaluating the long-term safety of ASC-40 (denifanstat) tablets in patients with moderate to severe acne. 3 February 2026
Biotechnology
The US Food and Drug Administration (FDA) last week lifted the clinical hold on Intellia Therapeutics’ investigational new drug (IND) for its nexiguran ziclumeran (nex-z) for amyloidosis. The US Centers for Medicare and Medicaid Services (CMS) has released the names of 15 more drugs for a third cycle of Medicare price negotiations. On the deal-making front, Moderna signed a commercialization collaboration with Italy’s Recordati on mRNA-3927, and Japan’s Kyowa Kirin revealed that its partner Amgen has terminated the collaboration on dermatology candidate rocatinlimab. 1 February 2026
Biotechnology
Japanese drugmaker Kyowa Kirin late Friday announced the termination of the current rocatinlimab development and commercialization collaboration with US biotech major Amgen. 31 January 2026
Biotechnology
US biotech major Regeneron has presented its financial results for the fourth quarter and full year 2025. 30 January 2026
Pharmaceutical
French pharma major Sanofi reported strong fourth-quarter and full-year results for 2025 on Thursday. 29 January 2026
Pharmaceutical
Spanish dermatology specialist Almirall has announced that China’s National Medical Products Administration (NMPA) has approved Seysara (sarecycline hydrochloride). 29 January 2026
Biotechnology
US drugmakers Moderna and Merck & Co last week released new data on the former’s intismeran autogene and Merck’s Keytruda in the treatment of melanoma. UK pharma major GSK announced an agreement to acquire RAPT Therapeutics, along with its ozureprubart for $2.2 billion. Johnson & Johnson was the first big pharma to announce fourth quarter 2025 financials and forecast further growth. Also of note, Janux Therapeutics entered a collaboration with Bristol Myers Squibb for its investigational oncology drug JANX007 that could earn the company $850 million. 25 January 2026
Biotechnology
Following the positive COAST 1 results in September 2025, two additional global Phase III studies – SHORE and COAST 2 of amlitelimab, a fully human non-T cell depleting monoclonal antibody that selectively targets OX40-ligand (OX40L), today delivered a robust body of evidence that supports amlitelimab’s potential in the treatment of patients 12 years and older with moderate-to-severe atopic dermatitis (AD). 23 January 2026
Pharmaceutical
French drugmaker Ipsen announced that the Arbitral Tribunal of the International Chamber of Commerce (ICC) has issued a final decision in favor of Ipsen, dismissing the claim initiated by Galderma in the arbitration proceedings related to Ipsen’s termination of the R&D agreement. 22 January 2026
Pharmaceutical
US healthcare giant Johnson & Johnson has announced results for fourth-quarter and full-year 2025. 21 January 2026
Biotechnology
Californian biopharma Corvus Pharmaceuticals has announced positive results from cohort four of the randomized, blinded, placebo-controlled Phase I trial of soquelitinib in moderate to severe atopic dermatitis. 21 January 2026
Biotechnology
USA-based mRNA vaccines company Moderna’s shares were flat in pre-market activity, as the company announced awaited new clinical data on its investigational mRNA-based individualized neoantigen therapy (INT). 20 January 2026
Pharmaceutical
US commercial-stage biopharma Pelthos Therapeutics has secured a senior secured term loan facility of up to $50 million from Horizon Technology Finance (Nasdaq: HRZN), with $30 million funded at closing and up to $20 million available if certain milestones are met. 14 January 2026
Biotechnology
Spanish dermatology specialist Almirall is using its appearance at the 44th JP Morgan Healthcare Conference in San Francisco to set out an active 2026 clinical agenda, leaning into proof-of-concept work across immune-driven skin diseases and pushing one bispecific antibody into first-in-human testing. 14 January 2026
Pharmaceutical
Royalty Pharma and the US affiliate of Israel’s Teva Pharmaceutical Industries have announced a funding agreement of up to $500 million to accelerate the clinical development of Teva’s anti-interleukin (IL)-15 antibody, TEV-'408. 12 January 2026
Biotechnology
The launch of USA-based Poplar Therapeutics has been announced, alongside a $50 million Series A financing led by SR One, Vida Ventures and Platanus. 8 January 2026
Biotechnology
Immune-mediated diseases specialist Alumis has announced positive top-line results from its Phase III ONWARD1 and ONWARD2 trials of envudeucitinib, a next-generation highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in moderate-to-severe plaque psoriasis. 7 January 2026
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze